Blog
RSS FeedPosted by Michael Wonder on 05 Jan 2017
New “21st Century Cures” legislation: speed and ease versus science
5 January 2017 - The 21st Century Cures Act was signed into law in December 2016. Praised by its advocates as ...
Posted by Michael Wonder on 04 Jan 2017
The changing face of clinical trials: the large pharmaceutical company perspective
4 January 2017 - Large pharmaceutical companies conduct clinical trials to evaluate efficacy and identify safety issues for candidate drugs as ...
Posted by Michael Wonder on 30 Dec 2016
FDA completes guidance on the development of biosimilars
29 December 2016 - Drug makers received guidance from the FDA on 28 December on the development of biosimilar medicines. ...
Posted by Michael Wonder on 27 Dec 2016
Negative control outcomes: a tool to detect bias in randomised trials
27 December 2016 - Investigators have several design, measurement, and analytic tools to detect and reduce bias in epidemiological studies. One ...
Posted by Michael Wonder on 22 Dec 2016
FDA officials call for including adolescents in adult oncology trials
20 December 2016 - A team of officials at the US FDA are calling for a "culture shift" by drug ...
Posted by Michael Wonder on 20 Dec 2016
Harnessing the U.S. taxpayer to fight cancer and make profits
19 December 2016 - Enthusiasm for cancer immunotherapy is soaring, and so is Arie Belldegrun’s fortune. ...
Posted by Michael Wonder on 15 Dec 2016
A new type of molecular medicine may be needed to halt cancers
16 December 2016 - Doctors must look to proteins rather than genes to tackle tumours. ...
Posted by Michael Wonder on 15 Dec 2016
Transforming evidence generation to support health and health care decisions
14 December 2016 - Making better choices about health and health care requires the best possible evidence. Unfortunately, many of the ...
Posted by Michael Wonder on 14 Dec 2016
The 21st Century Cures Act — a view from the NIH
14 December 2016 - The Cures Act, formally known as H.R. 34 or the 21st Century Cures Act, passed overwhelmingly in ...
Posted by Michael Wonder on 14 Dec 2016
Obama signs $6.3 billion law for cancer research, drug treatment
14 December 2016 - President Barack Obama has signed into law legislation that makes new investments in cancer research and battling ...
Posted by Michael Wonder on 08 Dec 2016
Interpreting geographic variations in results of randomised, controlled trials
7 December 2016 - Clinical triallists generally accept the premise that surprising results in subgroups of a randomised, controlled trial most ...
Posted by Michael Wonder on 08 Dec 2016
1 patient, 7 tumours and 100 billion cells equal 1 striking recovery
7 December 2016 - The remarkable recovery of a woman with advanced colon cancer, after treatment with cells from her ...
Posted by Michael Wonder on 29 Nov 2016
Quality of life, overall survival, and costs of cancer drugs approved based on surrogate endpoints
29 November 2016 - The lack of evidence of a clinically meaningful benefit for many cancer drugs approved by the US ...
Posted by Michael Wonder on 28 Nov 2016
Republicans reach deal to pass Cures Act by end of year, but Democrats pushing for changes
27 November 2016 - House and Senate leaders announced late Friday night that they had finally hammered out a deal ...
Posted by Michael Wonder on 17 Nov 2016
FDA research to help speed development of Zika virus vaccines and therapeutics
17 November 2016 - Neonatal mouse model provides a new platform for Zika virus research. ...